Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Genomic Health Inc's Business Segments
Genomic Health Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 114
Countrys Reported
1
Genomic Health Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Country - FY
- US83.4%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 95 | 83.4% |
Revenue by Product & Service Category - FY
- Product100%
- Invasive Breast Cancer Test72%
- Prostate Cancer Test8.2%
- Other Cancer Tests3.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 114 | 100% |
| Invasive Breast Cancer Test | $ 82 | 72% |
| Prostate Cancer Test | $ 9 | 8.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Genomic Health Inc dataset.
Description of Genomic Health Inc
Genomic Health Inc. is a precision medicine company that specializes in cancer diagnostics. It was founded in 2000 and is based in Redwood City, California. The company is dedicated to transforming cancer care through the development and commercialization of molecular diagnostic tests that provide physicians with a personalized approach to treating cancer patients.
Genomic Health's innovative tests use advanced genomic technology to analyze a patient's tumor to predict disease aggressiveness, response to treatment, and likelihood of recurrence. These tests help oncologists make more informed treatment decisions and provide patients with a more personalized approach to cancer care.
The company's flagship product is the Oncotype DX test, which is used to determine the likelihood of breast cancer recurrence and the benefit of chemotherapy after surgery. Oncotype DX analyzes the expression of 21 genes in a patient's tumor sample and generates a score that predicts the risk of recurrence. This test has been used to guide treatment decisions for over a million breast cancer patients worldwide.
In addition to the Oncotype DX test, Genomic Health has developed other diagnostic tests for prostate, colon, and lung cancers. The company is also developing new diagnostic products for other cancers, including melanoma, bladder cancer, and pancreatic cancer.
Genomic Health is committed to ensuring that its tests are accessible to all patients who need them. The company works closely with insurers, government agencies, and patient advocacy groups to ensure that its tests are covered by insurance and reimbursed at fair prices. Genomic Health also offers financial assistance programs to help low-income patients access its tests.
In 2019, Genomic Health was acquired by Exact Sciences, a leading precision oncology company. The two companies continue to work together to advance cancer diagnostics and treatment.
Genomic Health's innovative tests use advanced genomic technology to analyze a patient's tumor to predict disease aggressiveness, response to treatment, and likelihood of recurrence. These tests help oncologists make more informed treatment decisions and provide patients with a more personalized approach to cancer care.
The company's flagship product is the Oncotype DX test, which is used to determine the likelihood of breast cancer recurrence and the benefit of chemotherapy after surgery. Oncotype DX analyzes the expression of 21 genes in a patient's tumor sample and generates a score that predicts the risk of recurrence. This test has been used to guide treatment decisions for over a million breast cancer patients worldwide.
In addition to the Oncotype DX test, Genomic Health has developed other diagnostic tests for prostate, colon, and lung cancers. The company is also developing new diagnostic products for other cancers, including melanoma, bladder cancer, and pancreatic cancer.
Genomic Health is committed to ensuring that its tests are accessible to all patients who need them. The company works closely with insurers, government agencies, and patient advocacy groups to ensure that its tests are covered by insurance and reimbursed at fair prices. Genomic Health also offers financial assistance programs to help low-income patients access its tests.
In 2019, Genomic Health was acquired by Exact Sciences, a leading precision oncology company. The two companies continue to work together to advance cancer diagnostics and treatment.
Genomic Health Inc is a pioneering entity in the realm of genomic-based diagnostic testing, primarily focusing on cancer. The companys innovative approach aids healthcare professionals and patients in making informed decisions regarding personalized treatment strategies and disease management. Genomic Healths offerings are segmented mainly into breast cancer and prostate cancer, with a suite of products and services meticulously designed to meet the unique needs of patients and oncologists.
Segments:
1. Breast Cancer:
Genomic Health has developed a comprehensive range of diagnostic tools to address the complexities of breast cancer treatment. Among these products are:
- Oncotype DX Breast Recurrence Score: This test evaluates the expression of 21 genes in a breast tumor. Its primary function is to predict the likelihood of cancer recurrence over the next ten years, enabling oncologists to gauge the necessity of additional treatments such as chemotherapy. The results provide a score that assists physicians in making tailored treatment decisions, particularly in cases of early-stage, hormone receptor-positive breast cancer.
- Oncotype DX Breast DCIS Score: Aimed at patients diagnosed with ductal carcinoma in situ (DCIS), this test assesses the expression of 12 genes and predicts the likelihood of cancer recurrence following lumpectomy surgery. This helps guide management strategies for DCIS, allowing healthcare providers to better understand the risk versus benefit of various treatment options post-surgery.
Prostate Cancer:
In addition to breast cancer diagnostics, Genomic Health offers pivotal products for prostate cancer patients, which include:
- Oncotype DX Genomic Prostate Score (GPS): This test analyzes the activity of 17 genes within a prostate tumor sample to provide insights into the aggressiveness and potential progression of prostate cancer. The GPS score helps oncologists stratify patients according to their risk levels, thereby informing decisions on treatment methodologies, including active surveillance or more aggressive interventions.
Products:
1. Oncotype DX:
Oncotype DX constitutes a core component of Genomic Healths product line, serving as a robust genomic diagnostic platform. This platform evaluates specific gene activity in tumor samples, generating predictive insights into a patient’s risk of cancer recurrence, the anticipated response to various therapies, and potential benefits derived from chemotherapy. By integrating genomic data into clinical decision-making, Oncotype DX empowers oncologists to customize treatment plans specific to individual patient profiles, optimizing therapeutic outcomes.
Oncotype SEQ:
The Oncotype SEQ platform utilizes next-generation sequencing (NGS) technology to identify small genetic mutations within cancer cells. These mutations hold significant implications regarding how a patient may respond to specific treatment regimens. By delivering comprehensive mutation status information, Oncotype SEQ aids physicians in selecting the most effective therapeutic approaches, thus ensuring a more precise and personalized treatment journey for the patient.
Services:
1. Laboratory Services:
Genomic Health operates a cutting-edge clinical laboratory where all genomic diagnostic tests are performed. This facility is staffed by a dedicated team of scientists and technicians who are rigorously trained to ensure high standards of accuracy and efficiency in testing. The laboratorys capabilities enable rapid turnaround times for test results, which is crucial for timely patient management and therapy decisions.
Professional Services:
The professional services division at Genomic Health collaborates closely with healthcare providers, enhancing their understanding of genomic testing and its clinical applications. This team offers educational resources, clinical support, and ongoing training, facilitating healthcare providers engagement with the latest advancements in genomic medicine. This support is essential for ensuring that providers are well-equipped to offer evidence-based care that aligns with the latest insights from cancer genomics.
Summary:
In conclusion, Genomic Health Inc delivers an extensive portfolio of genomic-based diagnostic tests and services across two primary segments: breast cancer and prostate cancer. Their products, such as Oncotype DX and Oncotype SEQ, offer vital assessments that enable oncologists to personalize treatment and management strategies. The companys robust laboratory and professional services further enhance the value of its diagnostics, ensuring that healthcare professionals are knowledgeable and supported in their use of genomic insights to improve patient care outcomes. Through these offerings, Genomic Health is committed to advancing the precision and personalization of cancer treatment, ultimately benefiting patients and enhancing their treatment journeys.
Segments:
1. Breast Cancer:
Genomic Health has developed a comprehensive range of diagnostic tools to address the complexities of breast cancer treatment. Among these products are:
- Oncotype DX Breast Recurrence Score: This test evaluates the expression of 21 genes in a breast tumor. Its primary function is to predict the likelihood of cancer recurrence over the next ten years, enabling oncologists to gauge the necessity of additional treatments such as chemotherapy. The results provide a score that assists physicians in making tailored treatment decisions, particularly in cases of early-stage, hormone receptor-positive breast cancer.
- Oncotype DX Breast DCIS Score: Aimed at patients diagnosed with ductal carcinoma in situ (DCIS), this test assesses the expression of 12 genes and predicts the likelihood of cancer recurrence following lumpectomy surgery. This helps guide management strategies for DCIS, allowing healthcare providers to better understand the risk versus benefit of various treatment options post-surgery.
Prostate Cancer:
In addition to breast cancer diagnostics, Genomic Health offers pivotal products for prostate cancer patients, which include:
- Oncotype DX Genomic Prostate Score (GPS): This test analyzes the activity of 17 genes within a prostate tumor sample to provide insights into the aggressiveness and potential progression of prostate cancer. The GPS score helps oncologists stratify patients according to their risk levels, thereby informing decisions on treatment methodologies, including active surveillance or more aggressive interventions.
Products:
1. Oncotype DX:
Oncotype DX constitutes a core component of Genomic Healths product line, serving as a robust genomic diagnostic platform. This platform evaluates specific gene activity in tumor samples, generating predictive insights into a patient’s risk of cancer recurrence, the anticipated response to various therapies, and potential benefits derived from chemotherapy. By integrating genomic data into clinical decision-making, Oncotype DX empowers oncologists to customize treatment plans specific to individual patient profiles, optimizing therapeutic outcomes.
Oncotype SEQ:
The Oncotype SEQ platform utilizes next-generation sequencing (NGS) technology to identify small genetic mutations within cancer cells. These mutations hold significant implications regarding how a patient may respond to specific treatment regimens. By delivering comprehensive mutation status information, Oncotype SEQ aids physicians in selecting the most effective therapeutic approaches, thus ensuring a more precise and personalized treatment journey for the patient.
Services:
1. Laboratory Services:
Genomic Health operates a cutting-edge clinical laboratory where all genomic diagnostic tests are performed. This facility is staffed by a dedicated team of scientists and technicians who are rigorously trained to ensure high standards of accuracy and efficiency in testing. The laboratorys capabilities enable rapid turnaround times for test results, which is crucial for timely patient management and therapy decisions.
Professional Services:
The professional services division at Genomic Health collaborates closely with healthcare providers, enhancing their understanding of genomic testing and its clinical applications. This team offers educational resources, clinical support, and ongoing training, facilitating healthcare providers engagement with the latest advancements in genomic medicine. This support is essential for ensuring that providers are well-equipped to offer evidence-based care that aligns with the latest insights from cancer genomics.
Summary:
In conclusion, Genomic Health Inc delivers an extensive portfolio of genomic-based diagnostic tests and services across two primary segments: breast cancer and prostate cancer. Their products, such as Oncotype DX and Oncotype SEQ, offer vital assessments that enable oncologists to personalize treatment and management strategies. The companys robust laboratory and professional services further enhance the value of its diagnostics, ensuring that healthcare professionals are knowledgeable and supported in their use of genomic insights to improve patient care outcomes. Through these offerings, Genomic Health is committed to advancing the precision and personalization of cancer treatment, ultimately benefiting patients and enhancing their treatment journeys.